A Senate hearing on the FDA’s oversight of foreign drug manufacturing has heard from Sen. Chuck Grassley (R-Iowa that the CCP virus pandemic has highlighted the U.S. need for a “robust and aggressive” inspection program for drugs manufactured abroad.
Grassley, Chair of the Finance Committee, said on June 2 that the United States imports 13 percent of its active pharmaceutical ingredients (API) from China and 19 percent from India, while more than 70 percent of the facilities that make APIs are located abroad.
